22nd Century vs cbdMD
XXII and YCBD side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How XXII and YCBD compare
cbdMD is the larger company, worth 13 times as much as 22nd Century ($4.1M against $312K).
cbdMD grew revenue faster over the last twelve months (10.0% versus −27.4% for 22nd Century).
cbdMD keeps more of each dollar of sales as profit, with a net margin of −13.8% compared with −27.0% at 22nd Century.
cbdMD scores higher on the StockData Score (10 against 6 for 22nd Century), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | XXII | YCBD |
|---|---|---|
| Size and price | ||
| Market cap | $312K | $4.1M |
| Share price | $0.437 | $0.364 |
| Change, 1 year | −100.0% | −43.3% |
| Change, 5 years | −100% | −99.9% |
| Beta (5Y) | – | 2.27 |
| Employees | 32 | 42 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 3 | 3 |
| Growth score | 1 | 1 |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.0× (better) | 0.2× |
| P/B | 0.0× (better) | 0.5× |
| FCF yield | −2806% | −59.1% (better) |
| Fair value | $34.80 | $1.95 |
| Margin of safety | 98.7% (better) | 81.4% |
| Growth | ||
| Revenue growth (TTM) | −27.4% | 10.0% (better) |
| Revenue growth, 5Y average | −9.0% (better) | −14.5% |
| Profitability | ||
| Gross margin | 45.0% | 57.7% (better) |
| Operating margin | −85.0% | −13.9% (better) |
| Net margin | −27.0% | −13.8% (better) |
| FCF margin | −60.3% | −11.5% (better) |
| Return on equity | −32.4% (better) | −40.3% |
| Return on invested capital | −106% | −41.2% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −21.5× | – |
| Current ratio | 2.61 (better) | 2.50 |
| Altman Z-score | −22.20 | −17.58 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.3% | 8.2% |
| Held by insiders | 35.8% | 34.6% |
| Insider net buying, 12 months | – | −$1.3M |
| Short interest, % of float | 262% | 6.6% |
Go deeper
- XXII stock overview
- XXII income statement
- XXII valuation and score
- YCBD stock overview
- YCBD income statement
- YCBD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.